Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYNACIRC CR vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Hypertension
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
>95%, primarily to albumin and alpha-1 acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
2.8 L/kg, indicating extensive tissue distribution.
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral (CR): 20-30% due to first-pass metabolism.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
For GFR <30 m L/min, start at 2.5 mg orally once daily; titrate cautiously. No adjustment necessary for GFR >=30 m L/min.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
For Child-Pugh Class A or B: start at 2.5 mg orally once daily. For Child-Pugh Class C: avoid use due to lack of data.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Safety and effectiveness in pediatric patients have not been established.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Initial dose: 2.5 mg orally once daily. Titrate slowly due to increased sensitivity and risk of hypotension.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
None
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
May cause hypotension, especially in volume-depleted patients,Peripheral edema,Hepatic impairment may require dose adjustment,May increase angina or myocardial infarction in patients with obstructive coronary disease upon initiation or dose escalation
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to isradipine or any component,Cardiogenic shock,Acute myocardial infarction
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Grapefruit juice increases isradipine plasma concentrations; avoid concurrent use. High-fat meals may slightly delay absorption but no significant clinical effect.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
Isradipine (Dyna Circ CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times the maximum recommended human dose). However, embryotoxicity and fetotoxicity (increased resorptions, reduced fetal weight, delayed ossification) were observed at high doses. There are no adequate and well-controlled studies in pregnant women. Due to the potential risk of fetal harm, use only if the potential benefit justifies the risk. In the first trimester, avoid use if possible. In second and third trimesters, use with caution; may cause maternal hypotension and reduced uteroplacental perfusion.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Isradipine is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.6. Limited data suggest that infant exposure is low. However, due to the potential for adverse effects in the nursing infant (e.g., hypotension, cardiovascular effects), caution should be exercised. Use only if clearly needed and monitor the infant for signs of hypotension or bradycardia.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, increased renal clearance) may reduce isradipine concentrations. Empiric dose adjustment is not routinely recommended, but closer monitoring of blood pressure is advised. If inadequate response occurs, dose may be increased cautiously up to the maximum recommended dose (20 mg/day). No specific pregnancy dose adjustment guidelines exist; individualize therapy based on blood pressure response and tolerability.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
- DYNACIRC CR (isradipine controlled release) is a dihydropyridine calcium channel blocker used for hypertension. - The CR formulation allows once-daily dosing; avoid crushing or chewing tablets. - May cause dose-related peripheral edema, especially in higher doses or in elderly. - Use with caution in patients with aortic stenosis or in those with heart failure due to negative inotropic effects (though less than verapamil). - Grapefruit juice increases bioavailability; consider avoidance or dose adjustment. - Common side effects: headache, dizziness, flushing, and palpitations.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take exactly as prescribed once daily, preferably in the morning.,Swallow tablet whole; do not crush, chew, or split.,Avoid grapefruit juice while taking this medication.,Do not stop abruptly; may cause rebound hypertension.,Report persistent swelling in ankles/feet, palpitations, or severe dizziness.,May cause dizziness; avoid driving until you know how it affects you.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYNACIRC CR vs CALAN, answered by our medical review team.
DYNACIRC CR is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYNACIRC CR and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYNACIRC CR is: Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYNACIRC CR and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYNACIRC CR is classified as Category C. Isradipine (DynaCirc CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times . CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.